Nobivac L4

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
11-11-2021
Karakteristik produk Karakteristik produk (SPC)
11-11-2021

Bahan aktif:

Leptospira interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000), L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001), L. interrogans serogroup Australis serovar Bratislava (strain As-05-073), L. kirschneri serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)

Tersedia dari:

Intervet International BV

Kode ATC:

QI07AB01

INN (Nama Internasional):

Vaccine to prevent Leptospira infections in dogs

Kelompok Terapi:

Dogs

Area terapi:

Immunologicals

Indikasi Terapi:

For active immunisation of dogs against:Leptospira interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion;L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion;L. interrogans serogroup Australis serovar Bratislava to reduce infection;L. kirschneri serogroup Grippotyphosa serovar Bananal / Lianguang to reduce infection and urinary excretion.

Ringkasan produk:

Revision: 6

Status otorisasi:

Authorised

Tanggal Otorisasi:

2012-07-16

Selebaran informasi

                                13
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
LABEL
VIAL OF 1 ML
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac L4
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
See package leaflet.
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
1 ml
4.
ROUTE(S) OF ADMINISTRATION
SC
5.
WITHDRAWAL PERIOD(S)
Not applicable.
6.
BATCH NUMBER
Lot {number}
7.
EXPIRY DATE
EXP {month/year}
Once broached, use immediately.
8.
THE WORDS “FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
14
B.
PACKAGE LEAFLET
15
PACKAGE LEAFLET:
NOBIVAC L4
SUSPENSION FOR INJECTION FOR DOGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac L4 suspension for injection for dogs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
Inactivated
_Leptospira _
strains:
-
_L. interrogans _
serogroup Canicola serovar Portland-vere (strain Ca-12-000)
3550–7100 U
1
-
_L. interrogans _
serogroup Icterohaemorrhagiae serovar Copenhageni
(strain Ic-02-001)
290–1000 U
1
-
_L. interrogans _
serogroup Australis serovar Bratislava (strain As-05-073)
500–1700 U
1
-
_L. kirschneri _
serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)
650–1300 U
1
1
Antigenic mass ELISA units.
Colourless suspension.
4.
INDICATION(S)
For active immunisation of dogs against:
-
_L. interrogans_
serogroup Canicola serovar Canicola to reduce infection and urinary
excretion
-
_L. interrogans_
serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection
and urinary
excretion
-
_L._
_interrogans _
serogroup Australis serovar Bratislava to reduce infection
-
_L._
_kirschneri _
serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection
and urinary
excretion.
Onset of immunity
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac L4 suspension for injection for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
Inactivated
_Leptospira _
strains:
-
_L. interrogans _
serogroup Canicola serovar Portland-vere (strain Ca-12-000)
3550–7100 U
1
-
_L. interrogans _
serogroup Icterohaemorrhagiae serovar Copenhageni
(strain Ic-02-001)
290–1000 U
1
-
_L. interrogans _
serogroup Australis serovar Bratislava (strain As-05-073)
500–1700 U
1
-
_L. kirschneri _
serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)
650–1300 U
1
1
Antigenic mass ELISA units.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Colourless suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of dogs against:
-
_L. interrogans_
serogroup Canicola serovar Canicola to reduce infection and urinary
excretion
-
_L. interrogans_
serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection
and urinary
excretion
-
_L._
_interrogans _
serogroup Australis serovar Bratislava to reduce infection
-
_L._
_kirschneri _
serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection
and urinary
excretion.
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
4.5
SPECIAL PRECAUTIONS FOR USE
3
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Avoid accidental self-injection or contact with the eyes. In case of
ocular irritation seek medical
advice immediately and show the package leaflet or the label to the
physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
A mild and transient increase in body temperature (
≤
1 °C) has been observed very commonly in
clinical studies fo
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 11-11-2021
Karakteristik produk Karakteristik produk Bulgar 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Bulgar 29-01-2013
Selebaran informasi Selebaran informasi Spanyol 11-11-2021
Karakteristik produk Karakteristik produk Spanyol 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Spanyol 29-01-2013
Selebaran informasi Selebaran informasi Cheska 11-11-2021
Karakteristik produk Karakteristik produk Cheska 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Cheska 29-01-2013
Selebaran informasi Selebaran informasi Dansk 11-11-2021
Karakteristik produk Karakteristik produk Dansk 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Dansk 29-01-2013
Selebaran informasi Selebaran informasi Jerman 11-11-2021
Karakteristik produk Karakteristik produk Jerman 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Jerman 29-01-2013
Selebaran informasi Selebaran informasi Esti 11-11-2021
Karakteristik produk Karakteristik produk Esti 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Esti 29-01-2013
Selebaran informasi Selebaran informasi Yunani 11-11-2021
Karakteristik produk Karakteristik produk Yunani 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Yunani 29-01-2013
Selebaran informasi Selebaran informasi Prancis 11-11-2021
Karakteristik produk Karakteristik produk Prancis 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Prancis 29-01-2013
Selebaran informasi Selebaran informasi Italia 11-11-2021
Karakteristik produk Karakteristik produk Italia 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Italia 29-01-2013
Selebaran informasi Selebaran informasi Latvi 11-11-2021
Karakteristik produk Karakteristik produk Latvi 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Latvi 29-01-2013
Selebaran informasi Selebaran informasi Lituavi 11-11-2021
Karakteristik produk Karakteristik produk Lituavi 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Lituavi 29-01-2013
Selebaran informasi Selebaran informasi Hungaria 11-11-2021
Karakteristik produk Karakteristik produk Hungaria 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Hungaria 29-01-2013
Selebaran informasi Selebaran informasi Malta 11-11-2021
Karakteristik produk Karakteristik produk Malta 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Malta 29-01-2013
Selebaran informasi Selebaran informasi Belanda 11-11-2021
Karakteristik produk Karakteristik produk Belanda 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Belanda 29-01-2013
Selebaran informasi Selebaran informasi Polski 11-11-2021
Karakteristik produk Karakteristik produk Polski 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Polski 29-01-2013
Selebaran informasi Selebaran informasi Portugis 11-11-2021
Karakteristik produk Karakteristik produk Portugis 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Portugis 29-01-2013
Selebaran informasi Selebaran informasi Rumania 11-11-2021
Karakteristik produk Karakteristik produk Rumania 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Rumania 29-01-2013
Selebaran informasi Selebaran informasi Slovak 11-11-2021
Karakteristik produk Karakteristik produk Slovak 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Slovak 29-01-2013
Selebaran informasi Selebaran informasi Sloven 11-11-2021
Karakteristik produk Karakteristik produk Sloven 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Sloven 29-01-2013
Selebaran informasi Selebaran informasi Suomi 11-11-2021
Karakteristik produk Karakteristik produk Suomi 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Suomi 29-01-2013
Selebaran informasi Selebaran informasi Swedia 11-11-2021
Karakteristik produk Karakteristik produk Swedia 11-11-2021
Laporan Penilaian publik Laporan Penilaian publik Swedia 29-01-2013
Selebaran informasi Selebaran informasi Norwegia 11-11-2021
Karakteristik produk Karakteristik produk Norwegia 11-11-2021
Selebaran informasi Selebaran informasi Islandia 11-11-2021
Karakteristik produk Karakteristik produk Islandia 11-11-2021
Selebaran informasi Selebaran informasi Kroasia 11-11-2021
Karakteristik produk Karakteristik produk Kroasia 11-11-2021

Lihat riwayat dokumen